ArticleAmerican journal of preventive medicine2023
Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries.
Article in American journal of preventive medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care: A Cluster Randomized Clinical Trial.JAMA network open · 2026Trial
- Health Care Professional Willingness to Treat Opioid Use Disorder vs Type 2 Diabetes in Primary Care.JAMA network open · 2025Trial
- Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial.JAMA internal medicine · 2025Trial
- Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements.The Milbank quarterly · 2026Article
- Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Factors Associated with Primary Care, Behavioral Health, and Emergency Department Utilization Among Men with Opioid Use Disorder and Criminal-Legal Involvement: A Cross-Sectional Study.Research square · 2026Article
- Buprenorphine Microinduction Treatment in Tri-Diagnosis Patients with Opioid Use Disorder and Chronic Non-Cancerous Pain.Current pain and headache reports · 2026Review
- Initiating buprenorphine in New Jersey emergency departments: a mixed methods study.JEM reports · 2026Article
- Article
- Timely Receipt of New Medication Treatment After Acute Care Encounters for Opioid Overdose in the U.S. Medicaid Population.Journal of general internal medicine · 2026Article
- Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries.The American journal of drug and alcohol abuse · 2026Article
- Systemic Inertia in Addiction Care: Institutional Hesitancy and Ethical Barriers to Buprenorphine Initiation.Cureus · 2025Article
- States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018-24.Health affairs (Project Hope) · 2025Article
- Association of Medicare Advantage vs Traditional Medicare with Clinical Outcomes Among Patients Hospitalized for Substance Use Disorders.Journal of general internal medicine · 2025Article
- A Measurement Science Framework to Optimize CDS for Opioid Use Disorder Treatment in the ED.Applied clinical informatics · 2025Article
- Buprenorphine adherence among a prospective cohort of homeless-experienced adults with opioid use disorder.Drug and alcohol dependence · 2025Article
- Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing.Journal of substance use and addiction treatment · 2025Article
- A Narrative Review of Old and Emerging Treatment Modalities for Substance Use Disorders.Cureus · 2024Review
- How emergency departments are responding to the opioid crisis: Results from a statewide survey in Kentucky.Addiction science & clinical practice · 2024Article
- Barriers and Facilitators to Using a Clinical Decision Support Tool for Opioid Use Disorder in Primary Care.Journal of the American Board of Family Medicine : JABFM · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionOpioid-involved overdose mortality is a persistent public health challenge, yet limited evidence exists on the relationship between opioid use disorder treatment after a nonfatal overdose and subsequent overdose death.
methodsNational Medicare data were used to identify adult (aged 18-64 years) disability beneficiaries who received inpatient or emergency treatment for nonfatal opioid-involved overdose in 2008-2016. Opioid use disorder treatment was defined as (1) buprenorphine, measured using medication days' supply, and (2) psychosocial services, measured as 30-day exposures from and including each service date. Opioid-involved overdose fatalities were identified in the year after nonfatal overdose using linked National Death Index data. Cox proportional hazards models estimated the associations between time-varying treatment exposures and overdose death. Analyses were conducted in 2022.
resultsThe sample (N=81,616) was mostly female (57.3%), aged ≥50 years (58.8%), and White (80.9%), with a significantly elevated overdose mortality rate, compared with the general U.S. population (standardized mortality ratio=132.4, 95% CI=129.9, 135.0). Only 6.5% of the sample (n=5,329) had opioid use disorder treatment after the index overdose. Buprenorphine (n=3,774, 4.6%) was associated with a significantly lower risk of opioid-involved overdose death (adjusted hazard ratio=0.38, 95% CI=0.23, 0.64), but opioid use disorder-related psychosocial treatment (n=2,405, 2.9%) was not associated with risk of death (adjusted hazard ratio=1.18, 95% CI=0.71, 1.95).
conclusionsBuprenorphine treatment after nonfatal opioid-involved overdose was associated with a 62% reduction in the risk of opioid-involved overdose death. However, fewer than 1 in 20 individuals received buprenorphine in the subsequent year, highlighting a need to strengthen care connections after critical opioid-related events, particularly for vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.